FDA picks Dexcom as first participant in TEMPO digital health pilot

On Monday the U.S. Food and Drug Administration announced that Dexcom, the leading maker of continuous glucose monitors, will be the inaugural participant in its TEMPO digital‑health devices pilot. The move places the company at the front of an FDA‑run advisory program designed to shorten the gap between regulatory clearance and real‑world adoption for emerging digital‑health technologies.

Core developments

The FDA’s Center for Devices and Radiological Health said the TEMPO (Technology Evaluation and Modeling Pilot for Outcomes) program will pair manufacturers with agency experts early in the product‑development cycle. Participants receive guidance on study design, data‑generation strategies and pathways to reimbursement, with the goal of reducing the so‑called “valley of death” that stalls many digital‑health devices after clearance.

Dexcom’s selection was confirmed through a joint press release from the company and the FDA. According to the release, Dexcom will work with the agency over the coming months to shape the evidentiary framework for its next‑generation continuous glucose monitoring system, which is intended to improve accuracy, wearability and integration with automated insulin delivery platforms.

The pilot does not constitute a formal regulatory decision; rather, it offers a structured, collaborative forum where Dexcom can present data plans, receive feedback on clinical‑study endpoints, and explore how real‑world evidence can be leveraged for payer coverage. The FDA described the program as “a hands‑on, science‑driven approach to help innovators navigate the evidentiary landscape that underpins market success.”

While the FDA has not disclosed the exact timeline, the agency indicated that the pilot will run for an initial 12‑month period, after which outcomes will be evaluated and the program may be opened to additional companies.

Why it matters

Continuous glucose monitoring has transformed diabetes care, yet each new sensor generation still faces a steep climb to secure payer coverage and clinician adoption. The “valley of death” refers to the interval after a device receives FDA clearance but before it demonstrates sufficient real‑world value to justify reimbursement. For digital‑health firms, that gap can mean months or years of unmet revenue expectations and, for patients, delayed access to improved technology.

Dexcom’s CGM devices dominate the U.S. market, with roughly 70 % of users on its G6 system as of the latest market data. However, the company is already developing a sensor that promises longer wear time, reduced calibration, and tighter integration with closed‑loop insulin pumps. By entering the TEMPO pilot, Dexcom hopes to align its development plan with the evidentiary standards that insurers and clinicians increasingly demand.

The pilot also signals a broader shift in FDA strategy. Historically, the agency’s role has been largely reactive—reviewing submissions after a product is fully built. TEMPO flips that model, offering proactive, iterative advice that could accelerate the translation of digital innovations from lab to bedside. If successful, the program could become a template for other high‑risk, high‑reward technologies such as remote patient monitoring platforms, AI‑driven diagnostic tools and wearable therapeutics.

Differing viewpoints

Dexcom’s chief executive, in a statement released to investors, described the selection as “a validation of our commitment to evidence‑based innovation” and highlighted the company’s intention to “partner closely with the FDA to ensure that the next generation of our CGM delivers measurable health outcomes for people living with diabetes.”

FDA officials emphasized that the pilot is not a shortcut around the statutory review process. One senior advisor at the Center for Devices and Radiological Health noted that “early engagement does not replace the need for rigorous clinical data, but it does give companies a clearer roadmap to the data that matters most for patients and payers.”

Industry analysts offered a more cautious take. A health‑tech analyst at a major investment firm said that while the pilot could reduce uncertainty, “the ultimate test will be whether the FDA’s guidance translates into faster coverage decisions from Medicare, Medicaid and private insurers.” Another commentator from a patient‑advocacy organization warned that any accelerated pathway must still safeguard data privacy, especially as CGM devices generate continuous streams of personal health information.

What’s next

Over the next few weeks Dexcom is expected to submit a detailed evidence‑generation plan to the FDA, outlining proposed clinical studies, real‑world data sources and health‑economic models. The agency will review the plan, provide iterative feedback, and convene a series of advisory meetings that bring together regulators, payers, clinicians and patient representatives.

Should the collaboration produce a clear evidentiary framework, Dexcom could file supplemental applications that incorporate the FDA’s recommendations, potentially shortening the time to broader market acceptance. The agency has indicated that findings from the TEMPO pilot will be shared publicly, offering a playbook for other digital‑health innovators.

Beyond Dexcom, the FDA plans to open the TEMPO program to additional participants later in the year, focusing on devices that combine software, sensors and algorithms. The broader goal is to create a learning ecosystem where regulatory guidance, real‑world evidence and payer policy evolve together, reducing the attrition rate that has historically plagued digital‑health startups.